Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from Xencor ( (XNCR) ) is now available.
Xencor announced updates on its drug development pipeline, highlighting significant progress in several clinical and preclinical programs as of December 31, 2024. Key developments include new data on XmAb541’s selectivity for CLDN6, deep peripheral B-cell depletion observed with plamotamab in lymphoma patients, and resumed dose escalation for XmAb808. Additionally, the company has completed enrollment in three ongoing studies of vudalimab, marking important milestones towards advancing its portfolio of XmAb drug candidates. These advancements reinforce Xencor’s strategic focus on optimizing its antibody platforms to enhance patient outcomes and broaden its market presence in the biopharmaceutical industry.
More about Xencor
Xencor is a biotechnology company that focuses on the development of engineered antibody therapies, particularly in the oncology and autoimmune disease sectors. The company leverages its XmAb technology platforms to create bispecific T-cell engagers and other innovative antibody formats, which are designed to address complex biological challenges and improve therapeutic outcomes.
YTD Price Performance: -13.39%
Average Trading Volume: 617,303
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.44B
See more insights into XNCR stock on TipRanks’ Stock Analysis page.